thioctic acid has been researched along with Breast Cancer in 30 studies
Thioctic Acid: An octanoic acid bridged with two sulfurs so that it is sometimes also called a pentanoic acid in some naming schemes. It is biosynthesized by cleavage of LINOLEIC ACID and is a coenzyme of oxoglutarate dehydrogenase (KETOGLUTARATE DEHYDROGENASE COMPLEX). It is used in DIETARY SUPPLEMENTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This randomized double-blind placebo-controlled prospective study included 64 patients with breast cancer who were randomized into control group (n = 32) which received 4 cycles of doxorubicin plus cyclophosphamide (every 21 days) followed by weekly doses of paclitaxel for 12 weeks plus placebo tablets once daily and ALA group (n = 32) which received the same chemotherapeutic regimen plus ALA 600 once daily for 6 months." | 9.51 | Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients. ( Elshafiey, RA; Elzawawy, S; Ghoneim, A; Mostafa, TM; Werida, RH, 2022) |
| "Inositol has been reported to improve insulin sensitivity since it works as a second messenger achieving insulin-like effects on metabolic enzymes." | 9.17 | Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial. ( Botti, G; Brillante, G; Capasso, I; Cavalcanti, E; Ciliberto, G; Crispo, A; D'Aiuto, G; D'Aiuto, M; De Laurentiis, M; Esposito, E; Esposito, G; Frasci, G; Fucito, A; Grimaldi, M; Maurea, N; Montella, M, 2013) |
| " Motivated by the relatively high cytotoxic activity of gold complexes, such as Auranofin (approved to treat rheumatoid arthritis), for the treatment of various diseases, we anticipated that gold peptide bioconjugates would present interesting candidates for novel breast cancer therapies." | 7.91 | Bioconjugation of Cyclometalated Gold(III) Lipoic Acid Fragments to Linear and Cyclic Breast Cancer Targeting Peptides. ( Metzler-Nolte, N; Slootweg, JC; Śmiłowicz, D, 2019) |
| "To evaluate the efficacy of combination of alpha-lipoic acid and acetylcholinesterase inhibitor (ipidacrine hydrochloride) to prevent the development and improve the course of paclitaxel-induced peripheral neuropathy (PIPN) in patients with breast cancer according to the Total Neuropathy Score." | 5.51 | EVALUATION OF THE EFFICIENCY OF ALPHA-LIPOIC ACID AND IPIDACRINE HYDROCHLORIDE FOR THE PREVENTION OF PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY ACCORDING TO THE TOTAL NEUROPATHY SCORE. ( Holotiuk, IS; Holotiuk, SI; Holotiuk, VV; Kryzhanivska, AY; Maliborska, SV, 2022) |
| "This randomized double-blind placebo-controlled prospective study included 64 patients with breast cancer who were randomized into control group (n = 32) which received 4 cycles of doxorubicin plus cyclophosphamide (every 21 days) followed by weekly doses of paclitaxel for 12 weeks plus placebo tablets once daily and ALA group (n = 32) which received the same chemotherapeutic regimen plus ALA 600 once daily for 6 months." | 5.51 | Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients. ( Elshafiey, RA; Elzawawy, S; Ghoneim, A; Mostafa, TM; Werida, RH, 2022) |
| "To investigate the neurofunctional parameters in breast cancer (BC) patients with paclitaxel-induced peripheral neuropathy (PIPN) and to clarify the feasibility of using alpha-lipoic acid (ALA) in combination with the acetylcholinesterase inhibitor ipidacrine hydrochloride (IPD) for its prevention." | 5.51 | EFFECTIVENESS OF ALPHA-LIPOIC ACID AND IPIDACRINE HYDROCHLORIDE IN PREVENTION OF PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY ASSESSED BY ELECTRONEUROMYOGRAPHY OF SUPERFICIAL PERONEAL AND SURAL NERVES. ( Holotiuk, IS; Holotiuk, SI; Holotiuk, VV; Kryzhanivska, AY; Maliborska, SV, 2022) |
| " Lipoic acid alone or combined with paclitaxel can inhibit NF-κB expression and inhibit breast cancer cell proliferation." | 5.42 | Effect of lipoic acid combined with paclitaxel on breast cancer cells. ( Gong, Y; Hao, XY; Li, BJ; Ren, GH, 2015) |
| "Inositol has been reported to improve insulin sensitivity since it works as a second messenger achieving insulin-like effects on metabolic enzymes." | 5.17 | Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial. ( Botti, G; Brillante, G; Capasso, I; Cavalcanti, E; Ciliberto, G; Crispo, A; D'Aiuto, G; D'Aiuto, M; De Laurentiis, M; Esposito, E; Esposito, G; Frasci, G; Fucito, A; Grimaldi, M; Maurea, N; Montella, M, 2013) |
| " Motivated by the relatively high cytotoxic activity of gold complexes, such as Auranofin (approved to treat rheumatoid arthritis), for the treatment of various diseases, we anticipated that gold peptide bioconjugates would present interesting candidates for novel breast cancer therapies." | 3.91 | Bioconjugation of Cyclometalated Gold(III) Lipoic Acid Fragments to Linear and Cyclic Breast Cancer Targeting Peptides. ( Metzler-Nolte, N; Slootweg, JC; Śmiłowicz, D, 2019) |
| " In this study, we investigate secondary structure changes in the targeting protein Epidermal Growth Factor (EGF) during synthesis of theranostic bifunctional nanoparticle, devised for Photodynamic therapy of breast cancer." | 3.88 | FTIR study of secondary structure changes in Epidermal Growth Factor by gold nanoparticle conjugation. ( Bhattacharjee, TT; Castilho, ML; de Oliveira, IR; Hewitt, KC; Jesus, VPS; Raniero, L, 2018) |
| " Here, we report on reduction-sensitive reversibly crosslinked hyaluronic acid (HA) nanoparticles based on HA-Lys-LA conjugates (Lys: l-lysine methyl ester, LA: lipoic acid) for active targeting delivery of doxorubicin (DOX) to CD44+ breast cancers in vitro and in vivo, effectively overcoming drug resistance (ADR)." | 3.81 | Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts. ( Cheng, R; Deng, C; Meng, F; Xie, F; Zhang, J; Zhong, Y; Zhong, Z, 2015) |
| "Alopecia was evaluated by three independent reviewers using head photographs taken from four angles." | 2.90 | The utility of DHL-HisZnNa, a novel antioxidant, against anticancer agent-induced alopecia in breast cancer patients: a multicenter phase II clinical trial. ( Bando, H; Empuku, S; Hiratsuka, T; Inomata, M; Irie, Y; Ishida, M; Iwata, H; Kitano, S; Kondo, N; Kono, Y; Nakajima, K; Nishikawa, S; Ohno, S; Ohyama, T; Sagawa, N, 2019) |
| "In addition, DTX, a model drug for breast cancer treatment, was loaded (76." | 1.62 | A molybdenum oxide-based degradable nanosheet for combined chemo-photothermal therapy to improve tumor immunosuppression and suppress distant tumors and lung metastases. ( Ji, J; Kong, X; Liu, D; Qiu, N; Xi, Y; Yang, X; Ye, L; Zhai, G; Zhang, J; Zhang, Y, 2021) |
| "Breast cancer is the second most common cancer in the world." | 1.56 | Lipoic acid decreases breast cancer cell proliferation by inhibiting IGF-1R via furin downregulation. ( Farhat, D; Gadot, N; Ghayad, SE; Hussein, N; Icard, P; Le Romancer, M; Léon, S; Lincet, H, 2020) |
| "However, the effect of lipoic acid on breast cancer metastasis remains unclear." | 1.48 | α-Lipoic acid inhibits the migration and invasion of breast cancer cells through inhibition of TGFβ signaling. ( Elangovan, S; Suar, M; Thangaraju, M; Tripathy, A; Tripathy, J, 2018) |
| "PTP1B and SHP2 are overexpressed in breast cancer cells, thus inhibition of their activity can be potentially effective in breast cancer therapy." | 1.46 | Lipoic Acid Decreases the Viability of Breast Cancer Cells and Activity of PTP1B and SHP2. ( Gorska-Ponikowska, M; Kuban-Jankowska, A; Wozniak, M, 2017) |
| " Lipoic acid alone or combined with paclitaxel can inhibit NF-κB expression and inhibit breast cancer cell proliferation." | 1.42 | Effect of lipoic acid combined with paclitaxel on breast cancer cells. ( Gong, Y; Hao, XY; Li, BJ; Ren, GH, 2015) |
| "MDA-MB-231 cells, a human breast cancer cell line, were treated with various concentrations of LA (0, 250, 500, or 1000 mumol/L) to measure metastasis, MMP activity, and mRNA expression." | 1.36 | alpha-Lipoic acid reduces matrix metalloproteinase activity in MDA-MB-231 human breast cancer cells. ( Kim, WK; Lee, HS; Na, MH, 2010) |
| "Stimulation of breast cancer growth and inhibition of intestinal tumours by LA indicate that diverse growth control mechanisms are modulated by LA in different organs." | 1.35 | Intestinal tumour chemoprevention with the antioxidant lipoic acid stimulates the growth of breast cancer. ( Alberti, S; Antolini, L; Di Lena, A; La Sorda, R; Lattanzio, R; Patassini, C; Piantelli, M; Rossi, C, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (10.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.33) | 29.6817 |
| 2010's | 17 (56.67) | 24.3611 |
| 2020's | 9 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Qiu, N | 1 |
| Yang, X | 1 |
| Zhang, Y | 2 |
| Zhang, J | 3 |
| Ji, J | 1 |
| Kong, X | 1 |
| Xi, Y | 1 |
| Liu, D | 1 |
| Ye, L | 1 |
| Zhai, G | 1 |
| Holotiuk, IS | 2 |
| Kryzhanivska, AY | 2 |
| Holotiuk, SI | 2 |
| Maliborska, SV | 2 |
| Holotiuk, VV | 2 |
| Werida, RH | 1 |
| Elshafiey, RA | 1 |
| Ghoneim, A | 1 |
| Elzawawy, S | 1 |
| Mostafa, TM | 1 |
| Fang, H | 1 |
| Zhao, X | 1 |
| Gu, X | 1 |
| Sun, H | 1 |
| Cheng, R | 2 |
| Zhong, Z | 3 |
| Deng, C | 3 |
| Śmiłowicz, D | 1 |
| Slootweg, JC | 1 |
| Metzler-Nolte, N | 1 |
| Tripathy, J | 2 |
| Chowdhury, AR | 1 |
| Prusty, M | 1 |
| Muduli, K | 1 |
| Priyadarshini, N | 1 |
| Reddy, KS | 1 |
| Banerjee, B | 1 |
| Elangovan, S | 2 |
| Farhat, D | 2 |
| Léon, S | 1 |
| Ghayad, SE | 2 |
| Gadot, N | 1 |
| Icard, P | 2 |
| Le Romancer, M | 2 |
| Hussein, N | 2 |
| Lincet, H | 2 |
| Choi, HS | 1 |
| Kim, JH | 1 |
| Jang, SJ | 1 |
| Yun, JW | 1 |
| Kang, KM | 1 |
| Jeong, H | 1 |
| Ha, IB | 1 |
| Jeong, BK | 1 |
| Kuban-Jankowska, A | 1 |
| Gorska-Ponikowska, M | 1 |
| Wozniak, M | 1 |
| Nur, G | 1 |
| Nazıroğlu, M | 1 |
| Deveci, HA | 1 |
| Bhattacharjee, TT | 1 |
| Castilho, ML | 1 |
| de Oliveira, IR | 1 |
| Jesus, VPS | 1 |
| Hewitt, KC | 1 |
| Raniero, L | 1 |
| Tripathy, A | 1 |
| Thangaraju, M | 1 |
| Suar, M | 1 |
| Yang, H | 1 |
| Shen, W | 1 |
| Liu, W | 1 |
| Chen, L | 1 |
| Zhang, P | 1 |
| Xiao, C | 1 |
| Chen, X | 1 |
| Ling, L | 1 |
| Ismail, M | 1 |
| Du, Y | 1 |
| Yao, C | 2 |
| Li, X | 1 |
| Sagawa, N | 1 |
| Ohno, S | 1 |
| Hiratsuka, T | 1 |
| Kondo, N | 1 |
| Iwata, H | 1 |
| Bando, H | 1 |
| Ohyama, T | 1 |
| Ishida, M | 1 |
| Kono, Y | 1 |
| Nakajima, K | 1 |
| Empuku, S | 1 |
| Nishikawa, S | 1 |
| Irie, Y | 1 |
| Inomata, M | 1 |
| Kitano, S | 1 |
| Kothari, IR | 1 |
| Mazumdar, S | 1 |
| Sharma, S | 1 |
| Italiya, K | 1 |
| Mittal, A | 1 |
| Chitkara, D | 1 |
| Capasso, I | 1 |
| Esposito, E | 1 |
| Maurea, N | 1 |
| Montella, M | 1 |
| Crispo, A | 1 |
| De Laurentiis, M | 1 |
| D'Aiuto, M | 1 |
| Frasci, G | 1 |
| Botti, G | 1 |
| Grimaldi, M | 1 |
| Cavalcanti, E | 1 |
| Esposito, G | 1 |
| Fucito, A | 1 |
| Brillante, G | 1 |
| D'Aiuto, G | 1 |
| Ciliberto, G | 1 |
| Zhong, Y | 1 |
| Meng, F | 2 |
| Xie, F | 1 |
| Li, BJ | 1 |
| Hao, XY | 1 |
| Ren, GH | 1 |
| Gong, Y | 1 |
| Hu, C | 1 |
| Gu, F | 1 |
| Tai, Z | 1 |
| Gong, C | 1 |
| Xia, Q | 1 |
| Gao, Y | 1 |
| Gao, S | 1 |
| Sun, B | 1 |
| Fahmy, UA | 1 |
| Aljaeid, BM | 1 |
| Rossi, C | 1 |
| Di Lena, A | 1 |
| La Sorda, R | 1 |
| Lattanzio, R | 1 |
| Antolini, L | 1 |
| Patassini, C | 1 |
| Piantelli, M | 1 |
| Alberti, S | 1 |
| Dozio, E | 1 |
| Ruscica, M | 1 |
| Passafaro, L | 1 |
| Dogliotti, G | 1 |
| Steffani, L | 1 |
| Marthyn, P | 1 |
| Pagani, A | 1 |
| Demartini, G | 1 |
| Esposti, D | 1 |
| Fraschini, F | 1 |
| Magni, P | 1 |
| Lee, HS | 1 |
| Na, MH | 1 |
| Kim, WK | 1 |
| Savvov, VI | 2 |
| Karpov, LM | 2 |
| Richardson, SG | 1 |
| Killen, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Role of Alpha-Lipoic Acid Against Chemotherapy Induced Toxicities in Breast Cancer Patients[NCT03908528] | 64 participants (Actual) | Interventional | 2019-03-01 | Completed | |||
| Effects of Inositol Alone or Associated With Alpha-lipoic Acid in Polycystic Ovary Syndrome Treatment[NCT04881851] | 90 participants (Anticipated) | Interventional | 2015-05-07 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for thioctic acid and Breast Cancer
| Article | Year |
|---|---|
Lipoic acid-induced oxidative stress abrogates IGF-1R maturation by inhibiting the CREB/furin axis in breast cancer cell lines.
Topics: Breast Neoplasms; Cyclic AMP Response Element-Binding Protein; Female; Furin; Humans; MCF-7 Cells; N | 2020 |
5 trials available for thioctic acid and Breast Cancer
| Article | Year |
|---|---|
EVALUATION OF THE EFFICIENCY OF ALPHA-LIPOIC ACID AND IPIDACRINE HYDROCHLORIDE FOR THE PREVENTION OF PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY ACCORDING TO THE TOTAL NEUROPATHY SCORE.
Topics: Acetylcholinesterase; Aminoquinolines; Breast Neoplasms; Cholinesterase Inhibitors; Female; Humans; | 2022 |
Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotoxicity; Doxorubicin; Femal | 2022 |
EFFECTIVENESS OF ALPHA-LIPOIC ACID AND IPIDACRINE HYDROCHLORIDE IN PREVENTION OF PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY ASSESSED BY ELECTRONEUROMYOGRAPHY OF SUPERFICIAL PERONEAL AND SURAL NERVES.
Topics: Acetylcholinesterase; Breast Neoplasms; Female; Humans; Paclitaxel; Peripheral Nervous System Diseas | 2022 |
The utility of DHL-HisZnNa, a novel antioxidant, against anticancer agent-induced alopecia in breast cancer patients: a multicenter phase II clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Antioxidants; Breast Neoplasms; Com | 2019 |
Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial.
Topics: Aged; Biomarkers; Blood Glucose; Body Mass Index; Breast Neoplasms; Caloric Restriction; Cholesterol | 2013 |
24 other studies available for thioctic acid and Breast Cancer
| Article | Year |
|---|---|
A molybdenum oxide-based degradable nanosheet for combined chemo-photothermal therapy to improve tumor immunosuppression and suppress distant tumors and lung metastases.
Topics: Animals; Biocompatible Materials; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Doxorubicin; Fe | 2021 |
CD44-Targeted Multifunctional Nanomedicines Based on a Single-Component Hyaluronic Acid Conjugate with All-Natural Precursors: Construction and Treatment of Metastatic Breast Tumors
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Drug Carriers; Drug Delivery Systems; F | 2020 |
Bioconjugation of Cyclometalated Gold(III) Lipoic Acid Fragments to Linear and Cyclic Breast Cancer Targeting Peptides.
Topics: Antineoplastic Agents; Auranofin; Breast Neoplasms; Cell Line, Tumor; Cisplatin; Coordination Comple | 2019 |
α-Lipoic acid prevents the ionizing radiation-induced epithelial-mesenchymal transition and enhances the radiosensitivity in breast cancer cells.
Topics: Breast Neoplasms; Cell Movement; Epithelial-Mesenchymal Transition; Humans; Matrix Metalloproteinase | 2020 |
Lipoic acid decreases breast cancer cell proliferation by inhibiting IGF-1R via furin downregulation.
Topics: Breast Neoplasms; Cell Proliferation; Down-Regulation; Female; Furin; Humans; Receptor, IGF Type 1; | 2020 |
Synergistic Tumoricidal Effects of Alpha-Lipoic Acid and Radiotherapy on Human Breast Cancer Cells via HMGB1.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cellular Senescence; Chemoradiotherapy | 2021 |
Lipoic Acid Decreases the Viability of Breast Cancer Cells and Activity of PTP1B and SHP2.
Topics: Antineoplastic Agents; Antioxidants; Breast Neoplasms; Cell Survival; Humans; Leukocyte Common Antig | 2017 |
Synergic prooxidant, apoptotic and TRPV1 channel activator effects of alpha-lipoic acid and cisplatin in MCF-7 breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Breast Neoplasms; Cell Surv | 2017 |
FTIR study of secondary structure changes in Epidermal Growth Factor by gold nanoparticle conjugation.
Topics: Breast Neoplasms; Cell Line, Tumor; Chlorophyllides; Epidermal Growth Factor; ErbB Receptors; Female | 2018 |
α-Lipoic acid inhibits the migration and invasion of breast cancer cells through inhibition of TGFβ signaling.
Topics: Active Transport, Cell Nucleus; Angiopoietin-Like Protein 4; Animals; Breast Neoplasms; Cell Line, T | 2018 |
PEGylated Poly(α-lipoic acid) Loaded with Doxorubicin as a pH and Reduction Dual Responsive Nanomedicine for Breast Cancer Therapy.
Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Breast Neoplasms; Doxorubicin; Drug Delivery Sys | 2018 |
Lipoic acid-derived cross-linked liposomes for reduction-responsive delivery of anticancer drug.
Topics: Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Cell Proliferation; Cell Survival; Cross-Lin | 2019 |
Docetaxel and alpha-lipoic acid co-loaded nanoparticles for cancer therapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Docet | 2019 |
Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Topics: Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Chemistry, Pharmaceutical; Cross-Linking Rea | 2015 |
Effect of lipoic acid combined with paclitaxel on breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Cell Proliferation; Female; Humans; MCF-7 Cells; NF-kappa B; Paclitaxel | 2015 |
Synergistic effect of reduced polypeptide micelle for co-delivery of doxorubicin and TRAIL against drug-resistance in breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tum | 2016 |
Robust, active tumor-targeting and fast bioresponsive anticancer nanotherapeutics based on natural endogenous materials.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Breast Neoplasms; Cross-Linking Reagents; D | 2016 |
Combined strategy for suppressing breast carcinoma MCF-7 cell lines by loading simvastatin on alpha lipoic acid nanoparticles.
Topics: Apoptosis; Breast Neoplasms; Cell Survival; Female; Humans; MCF-7 Cells; Nanoparticles; Particle Siz | 2016 |
Intestinal tumour chemoprevention with the antioxidant lipoic acid stimulates the growth of breast cancer.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Antioxidants; Breast Neoplasms; Female; Intest | 2008 |
The natural antioxidant alpha-lipoic acid induces p27(Kip1)-dependent cell cycle arrest and apoptosis in MCF-7 human breast cancer cells.
Topics: Antioxidants; Apoptosis; Biological Products; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell P | 2010 |
alpha-Lipoic acid reduces matrix metalloproteinase activity in MDA-MB-231 human breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Antioxidants; Breast Neoplasms; Cell Line, Tumor; Cell Movement; | 2010 |
[Characteristics of 35S-lipoic acid absorption by the blood cells in breast cancer].
Topics: Absorption; Acute Disease; Adenocarcinoma, Scirrhous; Adenofibroma; Breast Neoplasms; Erythrocytes; | 1982 |
Metabolism of oestradiol by human mammary tumour 800 x g supernatants pretreated with dihydrolipoic acid.
Topics: Breast Neoplasms; Estradiol; Humans; Thioctic Acid; Tritium | 1977 |
[Pyruvate oxidation and S35-lipoic acid fixation by breast tumor homogenates].
Topics: Adenocarcinoma, Scirrhous; Adenofibroma; Breast Neoplasms; Female; Humans; In Vitro Techniques; Oxid | 1978 |